Funders › NY › Lymphoma Research Foundation › 2018
Grants paid by Lymphoma Research Foundation, tax year 2018
EIN 95-4335088 · New York, NY · Form 990, Schedule I · NTEE G80
In tax year 2018, Lymphoma Research Foundation (EIN 95-4335088) reported 15 grants paid totaling $1,340,000. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2018
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2018 | Duke University Medical Center Durham, NC | A | $250,000 | paid | Genome predictors of response in mantle cell lymphoma. | 201931269349301448 |
| 2018 | Hlee Moffitt Cancer Center & Research Institute Tampa, FL | A | $250,000 | paid | New Therapeutic Vulnerabilities for Ibrutinib Resistance Mantle Cell Lymphoma (MCL). | 201931269349301448 |
| 2018 | Children Research Institute Washington, DC | A | $225,000 | paid | Developing syngergistic immunetherapies for high risk Hodgkin Lymphoma. | 201931269349301448 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $225,000 | paid | Eradicating minimum residual disease | 201931269349301448 |
| 2018 | Dana-Farber Cancer Institute Boston, MA | A | $105,000 | paid | DECIPHERING THE ROLE FELLOWSHIP AWARD | 201931269349301448 |
| 2018 | Duke University Durham, NC | A | $105,000 | paid | THE TUMOR SUPPRESSIVE FELLOWSHIP AWARD | 201931269349301448 |
| 2018 | Columbia University Medical Center New York, NY | A | $100,000 | paid | Cancer care delivery and survival disparities in AYAs with Hodgkin lymphoma. | 201931269349301448 |
| 2018 | Baylor College of Medicine Houston, TX | A | $10,000 | paid | THE ROLE OF BIOLOGY | 201931269349301448 |
| 2018 | Health Research Incorporated Roswell Park Buffalo, NY | A | $10,000 | paid | Phase I/II Study of Pevonedistat with Rituximab and Ibrutinib for Relapsed/Refractory MCL. | 201931269349301448 |
| 2018 | Dana-Farber Cancer Institute Boston, MA | A | $10,000 | paid | A phase I/II trial of azacitidine plus venetoclax for the treatment of diffuse large B-cell Lymphoma. | 201931269349301448 |
| 2018 | Emory University Atlanta, GA | A | $10,000 | paid | Efficacy of bendamustine-obinutuzumab-venetoclax induction in untreated mantle cell lymphoma. | 201931269349301448 |
| 2018 | University of Washington Seattle, WA | A | $10,000 | paid | A Pilot Trial of TGR-1202 and Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma. | 201931269349301448 |
| 2018 | University of Rochester Rochester, NY | A | $10,000 | paid | Restoring mutant P53 function in B-cell lymphomas. | 201931269349301448 |
| 2018 | The Regents of the University of California Orange, CA | A | $10,000 | paid | Randomized phase II study of R-miniCHOP +/- oral azacytidine in elderly patients with DLBCL. | 201931269349301448 |
| 2018 | Mayo Clinic Rochester, MN | A | $10,000 | paid | Impact of Health Behaviors on Outcomes in Lymphoma Survivors: A Prospective Database and Pilot Study. | 201931269349301448 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.